New York, NY – According to filings with the U.S. Securities and Exchange Commission, Cell Source Inc. is raising $10,000,000.00 in a new round of investment. Sources indicate as part of senior management President and Chief Executive Officer, Itamar Shimrat played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cell Source Inc.

Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company’s patented Veto Cell technology represents a breakthrough in immune system management safe and selective tolerizing of immune response. This technology addresses one of the most fundamental challenges in human immunology: how to tune immune response so that it tolerates specific desirable foreign cells while continuing to attack all other potential threats. Our mission is to revolutionize the fields of transplantation, cancer treatment and reversal of vital organ disease, utilizing our breakthrough immune tolerance technology platform, in order to save lives, thus fulfilling the inspiring promise of immunotherapy.

To learn more about Cell Source Inc., visit http://cell-source.com/

Contact:
Itamar Shimrat, President and Chief Executive Officer
646-612-7554
https://www.linkedin.com/in/itamar-shimrat-4a96258/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved